Xeris Pharmaceuticals | XERS - Operating Expenses



Xeris Pharmaceuticals reported $67.06M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Adcock Ingram Holdings ZAR 4.23B 196.72M Dec/2024
Celltrion KRW 718.99B 24.68B Jun/2025
Cspc Pharmaceutical CNY 5.22B 248.9M Mar/2025
Dianthus Therapeutics USD 35.12M 1.88M Jun/2025
Divis Laboratories Ltd 17.93B 130M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Kangmei Pharma CNY 1.25B 35.75M Jun/2025
Knight Therapeutics CAD 89.06M 2.02M Sep/2024
Laboratorios Farma EUR 132.33M 179.02M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 19.8M 9.46M Dec/2024
Neuren Pharmaceuticals AUD 17.41M 2.86M Dec/2024
Organigram Holdings CAD 72.9M 18.86M Jun/2025
Pacira USD 170.87M 3.93M Jun/2025
Perrigo USD 1B 36.2M Jun/2025
Pharma Mar EUR 32.29M 9.66M Jun/2025
Qiagen NV USD 397.57M 39.27M Jun/2025
Sartorius EUR 722.5M 23.1M Jun/2025
Sino Biopharmaceutical CNY 11.66B 352.34M Dec/2024
Supernus Pharmaceuticals USD 153.31M 892K Jun/2025
Tilray USD 253.17M 16.55M Nov/2024
Zz Pientze Pharmaceu 1.68B 272.39M Jun/2025